Present and prospective clinical therapeutic regimens for Alzheimer’s disease
Open Access
- 1 September 2008
- journal article
- review article
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. 4 (4) , 765-777
Abstract
Dove Press is a member of the Open Access Initiative, specializing in peer reviewed Medical Journals. View articlesor submit your research for publishingKeywords
This publication has 109 references indexed in Scilit:
- An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic miceProceedings of the National Academy of Sciences, 2006
- MemantineDrugs, 2006
- A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's diseaseInternational Journal of Geriatric Psychiatry, 2005
- Persistent Amyloidosis following Suppression of Aβ Production in a Transgenic Model of Alzheimer DiseasePLOS Medicine, 2005
- Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studiesInternational Journal of Geriatric Psychiatry, 2005
- Anti‐amyloid activity of neprilysin in plaque‐bearing mouse models of Alzheimer's diseaseFEBS Letters, 2004
- Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving DonepezilJAMA, 2004
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- GalantamineDrugs, 2000
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984